Rezolute is currently conducting the following clinical studies:
An Open-Label Multiple-Dose Study of RZ358 in Patients with Congenital Hyperinsulinism. The study is currently enrolling patients. For patients or physicians interested in learning more about the study, please visit the clinicaltrials.gov entry NCT04538989 or visit the EU Clinical Trials Register entry 2016-004186-83 for more about sites in the US, EU and other participating countries.
Rezolute has announced the initiation of dosing in a Phase 1 first-in-human clinical study of RZ402, an investigational oral plasma kallikrein inhibitor (PKI), for the treatment of diabetic macular edema (DME). The study (RZ402-101) is a single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of RZ402 in healthy adult volunteers. The Company expects to complete the study in the first half of 2021.
Rezolute is committed to ensuring the safety of patients and volunteers who participate in any of our ongoing clinical trials. We strictly follow regulatory requirements to ensure the health and well-being of our participants at all times.